Community/Retail

Although women might benefit from fattier breakfasts, men could respond best to carbohydrates.

New findings show LYR-210's potential to significantly alleviate chronic rhinosinusitis symptoms, offering hope for patients with nasal inflammation and polyps.

New treatments for metabolic dysfunction-associated steatohepatitis (MASH)–related cirrhosis address unique challenges in drug development.

Amanda Gronniger, PharmD, CPh, BCCP, discusses practical strategies pharmacists can use to improve cholesterol management, from lifestyle counseling to emerging therapies.

Clairity Breast's FDA-approved AI platform revolutionizes breast cancer risk prediction, enhancing early detection and personalized prevention strategies.

Electronic prior authorization (EPA) technology can streamline the complex process of obtaining prior authorizations for GLP-1 medications.

The CDC has updated its COVID-19 vaccine guidance for children and pregnant individuals, sparking a debate among health experts and concerns over insurance coverage.

The NJSHP's 2nd Annual Symposium fosters networking and education for pharmacy professionals, featuring expert insights on compliance and regulation in pharmacy compounding.

Amid intensified scrutiny of COVID-19 vaccines at HHS, Moderna’s mRNA-1283 COVID-19 vaccine was granted FDA approval for patients 65 years and older and patients aged 12 to 64 years with at least 1 or more underlying risk factors for severe COVID-19.

The FDA designated Hadlima as an interchangeable biosimilar to Humira, enhancing patient access and potential savings for various conditions.

National Community Pharmacists Association President Jeff Harrell, PharmD, shares insights from this year’s event, highlighting its growing impact, the importance of engaging with policymakers, and the urgent issues facing independent pharmacies.

Explore how the gut microbiome influences cancer therapy responses, resistance mechanisms, and the potential of microbiota-focused strategies for improved outcomes.

Building on positive low-density lipoprotein cholesterol (LDL-C)-lowering seen in patients with atherosclerotic cardiovascular disease, inclisiran was found to induce meaningful and sustained LDL-C reductions following recent acute coronary syndrome.

The FDA grants fast track designation to TEV-53408, a promising treatment for celiac disease designed to address gluten intolerance and improve patient outcomes.

The announcement is set to affect multiple grants awarded to Moderna, which is developing mRNA-1018, a candidate vaccine against avian influenza.

Shore Medical Center enhances patient safety with a pharmacy-driven intravenous to oral opioid conversion protocol, minimizing risks and improving pain management.

The pharmacy is proud to be community focused and patient centered.

CKD is a complication of diabetes. Emerging treatments aim to optimize management and reduce risks. Pharmacists are key in applying new evidence to clinical practice.

V114, a 15-valent pneumococcal conjugate vaccine (PCV), provided better protection against serotypes 22F and 33F compared with 13-valent PCV (PCV13).

The formulation allows for individualized treatment in children with adrenocortical insufficiency.

New research highlights the significant cardiovascular risks associated with RSV, emphasizing the need for vaccination to protect vulnerable populations.

FDA approves acoltremon ophthalmic solution, a groundbreaking treatment for dry eye disease, enhancing natural tear production and patient quality of life.

The FDA approved the MenQuadfi vaccine for young children, enhancing protection against invasive meningococcal disease and its severe complications.

Real change often begins within pharmacies.

Pharmacists have an evolving role in biotechnology.

The expert explored the complex prior authorization process for GLP-1 medications, discussing challenges in documentation and medical necessity.

The change is poised to impact countless individuals who may have sought a COVID-19 vaccine this upcoming respiratory season.

Following a meeting of the Vaccines and Related Biological Products Advisory Committee, the FDA announced its recommendation of COVID-19 vaccines targeting LP.8.1, a strain of the JN.1 variant that has become dominant in the US.

Pharmacists can counsel patients and educate the health care team about the risks of pharmacologically caused illnesses.